Adagio Medical Holdings, Inc. reported significant financial challenges in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded no revenue for the three and nine months ended September 30, 2025, a stark decline from $132,000 and $333,000 in the same periods of the previous year. This drop is attributed to a strategic pause in commercial activities in Europe, which included a repurchase of previously sold inventory. The company’s accumulated deficit has now reached $92.3 million, up from $70.6 million at the end of 2024.
Operating expenses for the third quarter totaled $5.7 million, an increase from $4.6 million in the same quarter last year. This rise was driven by higher research and development costs, which amounted to $2.8 million, reflecting a 12.4% increase compared to the previous year. Selling, general, and administrative expenses remained relatively stable at $2.9 million, down from $4.9 million, primarily due to reduced payroll expenses following a corporate prioritization initiative. The net loss for the quarter was $10.1 million, compared to a net income of $3.6 million in the prior year, highlighting the financial strain the company is currently facing.
In terms of operational developments, Adagio Medical is focused on advancing its proprietary Ultra-Low Temperature Cryoablation (ULTC) technology for treating cardiac arrhythmias. The company has completed enrollment in its pivotal FULCRUM-VT clinical trial, which evaluates its vCLAS Cryoablation System. This system received Breakthrough Device designation from the FDA in April 2025, and the company plans to submit results for FDA approval in the first half of 2026. Additionally, Adagio is developing a next-generation ULTC catheter designed to enhance usability and efficiency in clinical settings.
As of September 30, 2025, Adagio had cash and cash equivalents of $4.7 million, a significant decrease from $20.6 million at the end of 2024. The company reported net cash used in operating activities of $14.9 million for the nine months ended September 30, 2025, compared to $6.4 million in the same period last year. To bolster its financial position, Adagio announced a private placement in October 2025, which is expected to generate approximately $19 million in gross proceeds, potentially providing the necessary liquidity to fund ongoing operations and development activities.
Looking ahead, Adagio Medical Holdings anticipates continued operating losses and negative cash flows as it navigates the complexities of product development and regulatory approval processes. The company emphasizes the need for additional capital to support its growth initiatives, including clinical trials and product commercialization. The management remains cautious, acknowledging that future funding will depend on various factors, including market conditions and the success of its product offerings.
About Adagio Medical Holdings, Inc.
Adagio Medical Holdings, Inc. develops and commercializes catheter-based cryoablation technologies for treating cardiac arrhythmias, primarily ventricular tachycardia. Its proprietary Ultra Low Temperature Cryoablation (ULTC) and Pulsed Field Cryoablation (PFCA) systems aim to improve ablation efficacy and safety. Serving the electrophysiology market, the company focuses on device innovation, regulatory approval, and clinical validation to address large, underserved patient populations worldwide.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.